Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

Journal of Virology

Volumn 77, Issue 21, 2003, Pages 11436-11447

  Huang, Claire Y H ^a   Butrapet, Siritorn ^a,b   Tsuchiya, Kiyotaka R ^a   Bhamarapravati, Natth ^b   Gubler, Duane J ^a   Kinney, Richard M ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE 2 PDK 53 VACCINE; DENGUE VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ATTENUATION; CHIMERA; CONTROLLED STUDY; DENGUE 2 PDK 53 VIRUS; DENGUE VIRUS; DENGUE VIRUS D1 16007; DENGUE VIRUS D2 16681; DENGUE VIRUS D3 16562; DENGUE VIRUS D4 1036; DENGUE VIRUS PDK53 E; DENGUE VIRUS PDK53 V; DRUG FORMULATION; ENVELOPE GENE; GENE EXPRESSION; GENE LOCUS; GENETIC VARIABILITY; IMMUNIZATION; MOUSE; NEUROVIRULENCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PRM GENE; STRUCTURAL GENE; TEMPERATURE SENSITIVITY; VACCINE PRODUCTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TYPING; VIRUS VIRULENCE;

ANIMALS; ANIMALS, SUCKLING; CELL LINE; DENGUE; DENGUE VIRUS; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; PLAQUE ASSAY; RECOMBINATION, GENETIC; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 0142092447     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.21.11436-11447.2003     Document Type: Article

References (45)

1. Allison, S. L., K. Stiasny, K. Stadler, C. W. Mandl, and F. X. Heinz. 1999. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J. Virol. 73:5605-5612.
2. Arroyo, J., F. Guirakboo, S. Fenner, Z. X. Zhang, T. P. Monath, and T. J. Chambers. 2001. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol. 75:934-942.
3. Bhamarapravati, N., and Y. Sutee. 2000. Live attenuated tetravalent dengue vaccine. Vaccine 18(Suppl. 2):44-47.
4. Bhamarapravati, N., and S. Yoksan. 1997. Live attenuated tetravalent vaccine, p. 367-377. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, Wallingford, United Kingdom.
5. Bhamarapravati, N., and S. Yoksan. 1989. Study of bivalent dengue vaccine in volunteers. Lancet i:1077.
6. Bhamarapravati, N., S. Yoksan, T. Chayaniyayothin, S. Angsubphakorn, and A. Bunyaratvej. 1987. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull. W. H. O. 65:189-195.
7. Bhatt, T. R., M. B. Crabtree, F. Guirakboo, T. P. Monath, and B. R. Miller. 2000. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg. 62:480-484.
8. Bray, M., R. Men, and C. J. Lai. 1996. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70:4162-4166.
9. Butrapet, S., C. Y.-H. Huang, D. J. Pierro, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2000. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74:3011-3019.
10. Butrapet, S., J. Rabablert, S. Angsubhakorn, W. Wiriyarat, C. Huang, R. Kinney, S. Punyim, and N. Bhamarapravati. 2002. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys. Southeast Asian J. Trop. Med. Public Health 33:589-599.
11. Cahour, A., A. Pletnev, M. Vazielle-Falcoz, L. Rosen, and C. J. Lai. 1995. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 207:68-76.
12. Chambers, T. J., Y. Liang, D. A. Droll, J. J. Schlesinger, A. D. Davidson, P. J. Wright, and X. Jiang. 2003. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J. Virol. 77:3655-3668.
13. Chen, B. Q., and B. J. Beaty. 1982. Japanese encephalitis vaccine (2-8 strain) and parent (SA 14 strain) viruses in Culex tritaeniorhynchus mosquitoes. Am. J. Trop. Med. Hyg. 31:403-407.
14. Dharakul, T., I. Kurane, N. Bhamarapravati, S. Yoksan, D. W. Vaughn, C. H. Hoke, and F. A. Ennis. 1994. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J. Infect. Dis. 170:27-33.
15. Durbin, A. P., R. A. Karron, W. Sun, D. W. Vaughn, M. J. Reynolds, J. R. Perreault, B. Thumar, R. Men, C. J. Lai, W. R. Elkins, R. M. Chanock, B. R. Murphy, and S. S. Whitehead. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am. J. Trop. Med. Hyg. 65:405-413.
16. Gubler, D. J., and M. Meltzer. 1999. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 53:35-70.
17. Guirakhoo, F., J. Arroyo, K. V. Pugachev, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, M. Ratterree, and T. P. Monath. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-7304.
18. Guirakhoo, F., K. Pugachev, J. Arroyo, C. Miller, Z. X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Draper, and T. P. Monath. 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159.
19. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
20. Halstead, S. B., and P. Simasthien. 1970. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J. Biol. Med. 42:276-292.
21. Huang, C. Y.-H., S. Butrapet, D. J. Pierro, G. J. Chang, A. R. Hunt, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2000. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74:3020-3028.
22. Jirakanjanakit, N., M. M. Khin, S. Yoksan, and N. Bhamarapravati. 1999. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 61:672-676.
23. Johnson, A. J., and J. T. Roehrig. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
24. Johnson, B. W., T. V. Chambers, M. B. Crabtree, T. R. Bhatt, F. Guirakhoo, T. P. Monath, and B. R. Miller. 2002. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am. J. Trop. Med. Hyg. 67:260-265.
25. Kanesa-thasan, N., W. Sun, G. Kim-Ahn, S. Van Albert, J. R. Putnak, A. King, B. Raengsakulsrach, H. Christ-Schmidt, K. Gilson, J. M. Zahradnik, D. W. Vaughn, B. L. Innis, J. F. Saluzzo, and C. H. Hoke, Jr. 2001. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19:3179-3188.
26. Kawano, H., V. Rostapshov, L. Rosen, and C. J. Lai. 1993. Genetic determinants of dengue type 4 virus neurovirulence for mice. J. Virol. 67:6567-6575.
27. Khin, M. M., N. Jirakanjanakit, S. Yoksan, and N. Bhamarapravati. 1994. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 51:864-869.
28. Khromykh, A. A., and E. G. Westaway. 1997. Subgenomic replicons of the flavivirus Kunjin: construction and applications. J. Virol. 71:1497-1505.
29. Kinney, R. M., S. Butrapet, G. J. Chang, K. R. Tsuchiya, J. T. Roehrig, N. Bhamarapravati, and D. J. Gubler. 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230:300-308.
30. Kinney, R. M., and C. Y.-H. Huang. 2001. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 44:176-197.
31. Kurane, I., and T. Takasaki. 2001. Dengue fever and dengue haemorrhagic fever: challenges of controlling an enemy still at large. Rev. Med. Virol. 11:301-311.
32. Lai, C. J., M. Bray, R. Men, A. Cahour, W. Chen, H. Kawano, M. Tadano, K. Hiramatsu, I. Tokimatsu, A. Pletnev, S. Arakai, G. Shameem, and M. Rinaudo. 1998. Evaluation of molecular strategies to develop a live dengue vaccine. Clin. Diagn. Virol. 10:173-179.
33. Miller, B. R., and D. Adkins. 1988. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol. 32:227-234.
34. Miller, B. R., B. J. Beaty, T. H. Aitken, K. H. Eckels, and P. K. Russell. 1982. Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti. Am. J. Trop. Med. Hyg, 31:1232-1237.
35. Morens, D. M. 1994. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin. Infect. Dis. 19:500-512.
36. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375:291-298.
37. Rice, C. M. 1996. Flaviviridae: the viruses and their replication, p. 931-959. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
38. Rothman, A. L. 1997. Viral pathogenesis of dengue infections, p. 245-272. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, Wallingford, United Kingdom.
39. Rothman, A. L., and F. A. Ennis. 1999. Immunopathogenesis of dengue hemorrhagic fever. Virology 257:1-6.
40. Rothman, A. L., N. Kanesa-thasan, K. West, J. Janus, J. F. Saluzzo, and F. A. Ennis. 2001. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 19:4694-4699.
41. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakul, K. Pengsaa, C. Pojjaroen-Anant, W. Chokejindachai, A. Jagsudee, J. F. Saluzzo, and N. Bhamarapravati. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
42. Schoepp, R. J., B. J. Beaty, and K. H. Eckels. 1991. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation. Am. J. Trop. Med. Hyg. 45:202-210.
43. Troyer, J. M., K. A. Hanley, S. S. Whitehead, D. Strickman, R. A. Karron, A. P. Durbin, and B. R. Murphy. 2001. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am. J. Trop. Med. Hyg. 65:414-419.
44. Vaughn, D. W., C. H. Hoke, Jr., S. Yoksan, R. LaChance, B. L. Innis, R. M. Rice, and N. Bhamarapravati. 1996. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14:329-336.
45. Yoksan, S., N. Bhamarapravati, and S. B. Halstead. 1986. Dengue virus vaccine development: study on biological markers of uncloned dengue 1-4 viruses serially passaged in primary kidney cells, p. 35-38. In T. D. St. George, B. H. Kay, and J. Blok (ed.), Arbovirus research in Australia. Proceedings of the 4th Symposium. CSIRO/QIMR, Brisbane, Australia.